Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of a breast cancer vaccine (SV-BR-1-GM) and
how well it works in combination with pembrolizumab for the treatment of breast cancer that
is persistent, has come back (recurrent), or has spread to other places in the body
(metastatic). Breast cancer vaccine SV-BR-1-GM is a human breast cancer cell line that has
been genetically engineered to produce a substance called "GM-CSF" (granulocyte-macrophage
colony stimulating factor) which occurs naturally in the body. GM-CSF is normally produced by
white blood cells and helps the body develop immunity to disease-causing germs. Immunotherapy
with monoclonal antibodies such as pembrolizumab may help the body's immune system attack the
cancer and may interfere with the ability of tumor cells to grow and spread. Anti-cancer
drugs such as cyclophosphamide may help boost the immune response. Interferon alpha 2b may
help stimulate the immune system to fight cancer. This trial may help doctors see whether
SV-BR-1-GM injections help boost the immune system and/or help control or help shrink breast
cancer along with the other drugs that also boost the immune system.